بالوکساویر ماربوکسیل (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "بالوکساویر ماربوکسیل" in Persian language version.

refsWebsite

Global rank Persian rank

10web.archive.org

1^st place

7nih.gov

4^th place

5^th place

3doi.org

2^nd place

2fda.gov

447^th place

382^nd place

1tga.gov.au

3,984^th place

1,143^rd place

1canada.ca

1,712^th place

2,923^rd place

1hres.ca

low place

1huatengsci.com

low place

1drugs.com

399^th place

104^th place

1worldcat.org

5^th place

12^th place

1semanticscholar.org

11^th place

52^nd place

canada.ca

health-products.canada.ca

"Xofluza Product information". Health Canada. 25 April 2012. Archived from the original on 12 August 2022. Retrieved 29 May 2022.

doi.org

Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. (December 2018). "In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit". Antiviral Res. 160: 109–117. doi:10.1016/j.antiviral.2018.10.008. PMID 30316915.
Eisfeld AJ, Neumann G, Kawaoka Y (January 2015). "At the centre: influenza A virus ribonucleoproteins". Nature Reviews. Microbiology. 13 (1): 28–41. doi:10.1038/nrmicro3367. PMC 5619696. PMID 25417656.
O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.

drugs.com

"Baloxavir Marboxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 19 August 2019. Archived from the original on 7 October 2019. Retrieved 9 January 2020.

fda.gov

"FDA approves new drug to treat influenza" (Press release). U.S. Food and Drug Administration (FDA). 24 October 2018. Archived from the original on 24 October 2019. Retrieved 23 October 2019. This article incorporates text from this source, which is in the public domain.
Food and Drug Administration (23 July 2019). "Drug Trial Snapshot: Xofluza". U.S. Food and Drug Administration (FDA). Archived from the original on 12 December 2019. Retrieved 7 January 2020. This article incorporates text from this source, which is in the public domain.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Xofluza". وزارت بهداشت کانادا. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

huatengsci.com

en.huatengsci.com

"Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects". Huateng Pharma. Archived from the original on 24 February 2021. Retrieved 29 May 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. (December 2018). "In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit". Antiviral Res. 160: 109–117. doi:10.1016/j.antiviral.2018.10.008. PMID 30316915.
Eisfeld AJ, Neumann G, Kawaoka Y (January 2015). "At the centre: influenza A virus ribonucleoproteins". Nature Reviews. Microbiology. 13 (1): 28–41. doi:10.1038/nrmicro3367. PMC 5619696. PMID 25417656.
O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.

dailymed.nlm.nih.gov

"Xofluza- baloxavir marboxil tablet, film coated". DailyMed. 28 October 2019. Archived from the original on 28 October 2020. Retrieved 9 January 2020.
"Xofluza- baloxavir marboxil tablet, film coated". DailyMed. 28 October 2019. Archived from the original on 28 October 2020. Retrieved 9 January 2020.

ncbi.nlm.nih.gov

Eisfeld AJ, Neumann G, Kawaoka Y (January 2015). "At the centre: influenza A virus ribonucleoproteins". Nature Reviews. Microbiology. 13 (1): 28–41. doi:10.1038/nrmicro3367. PMC 5619696. PMID 25417656.
O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.

semanticscholar.org

api.semanticscholar.org

O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.

tga.gov.au

"Xofluza Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 2 March 2020. Archived from the original on 13 March 2020. Retrieved 16 August 2020.

web.archive.org

"Xofluza Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 2 March 2020. Archived from the original on 13 March 2020. Retrieved 16 August 2020.
"Xofluza Product information". Health Canada. 25 April 2012. Archived from the original on 12 August 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Xofluza". وزارت بهداشت کانادا. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
"Xofluza- baloxavir marboxil tablet, film coated". DailyMed. 28 October 2019. Archived from the original on 28 October 2020. Retrieved 9 January 2020.
"Xofluza- baloxavir marboxil tablet, film coated". DailyMed. 28 October 2019. Archived from the original on 28 October 2020. Retrieved 9 January 2020.
"FDA approves new drug to treat influenza" (Press release). U.S. Food and Drug Administration (FDA). 24 October 2018. Archived from the original on 24 October 2019. Retrieved 23 October 2019. This article incorporates text from this source, which is in the public domain.
"Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects". Huateng Pharma. Archived from the original on 24 February 2021. Retrieved 29 May 2020.
"Baloxavir Marboxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 19 August 2019. Archived from the original on 7 October 2019. Retrieved 9 January 2020.
Food and Drug Administration (23 July 2019). "Drug Trial Snapshot: Xofluza". U.S. Food and Drug Administration (FDA). Archived from the original on 12 December 2019. Retrieved 7 January 2020. This article incorporates text from this source, which is in the public domain.
O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.

worldcat.org

O'Hanlon, Ryan; Shaw, Megan L. (April 2019). "Baloxavir marboxil: the new influenza drug on the market". Current Opinion in Virology. 35: 14–18. doi:10.1016/j.coviro.2019.01.006. ISSN 1879-6265. PMID 30852344. S2CID 73726080. Archived from the original on 4 November 2021. Retrieved 28 September 2020.